Working… Menu
Trial record 7 of 2571 for:    "Plasma Cell Neoplasm"

Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00432458
Recruitment Status : Completed
First Posted : February 7, 2007
Results First Posted : July 4, 2012
Last Update Posted : July 4, 2012
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Mayo Clinic

Brief Summary:

RATIONALE: Zoledronate may prevent bone loss and stop the growth of cancer cells in bone. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. It is not yet know whether giving zoledronate together with thalidomide is more effective than zoledronate alone in treating multiple myeloma.

PURPOSE: This randomized phase III trial is studying zoledronate and thalidomide see how well they work compared with zoledronate alone in treating patients with early stage multiple myeloma.

Condition or disease Intervention/treatment Phase
Multiple Myeloma and Plasma Cell Neoplasm Drug: Thalidomide Drug: zoledronic acid Phase 3

Detailed Description:



  • Compare time to progression in patients with early stage multiple myeloma treated with zoledronate with or without thalidomide.


  • Compare the response rate, 1-year progression-free survival rate, duration of response, and time to next therapy in patients treated with these regimens.
  • Assess differences in toxicity of these regimens in these patients.

OUTLINE: This is a multicenter, randomized study. Patients are stratified according to the presence of lytic lesions on metastatic bone survey (yes vs no), beta-2 microglobulin level (high vs normal), and bone marrow labeling index (high [> 1.0%] vs low [≤ 1.0%]). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oral thalidomide on days 1-28. Treatment with thalidomide repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive zoledronate IV over 15 minutes on day 1. Treatment with zoledronate repeats every 84 days for 1 year and once a year thereafter in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive zoledronate IV over 15 minutes on day 1. Treatment repeats every 84 days for 1 year and once a year thereafter in the absence of disease progression or unacceptable toxicity.

Blood samples are collected for research studies at baseline and after courses 3, 6, 9, and 12. Bone marrow aspirates are performed at baseline and after courses 6 and 12. Samples are evaluated for bone marrow angiogenesis; vascular endothelial growth factor (VEGF), VEGF receptor 1 (VEGFR-1), and VEGFR-2 expression; bone marrow angiogenesis-VEGF relationship; bone marrow angiogenesis/apoptosis rate relationship; bone marrow angiogenesis/plasma cell (PC) proliferation rate relationship; VEGF expression/apoptosis rate relationship; and VEGFR expression/PC proliferation rate relationship.

After completion of study treatment, patients are followed every 6 months for up to 5 years.

PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 68 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III Randomized Trial of Thalidomide Plus Zoledronic Acid Versus Zoledronic Acid Alone in Patients With Early Stage Multiple Myeloma
Study Start Date : July 2003
Actual Primary Completion Date : June 2011
Actual Study Completion Date : April 2012

Arm Intervention/treatment
Experimental: Arm I: Thal/ZLD
Thalidomide (Thal) + Zolendronic acid (ZLD)
Drug: Thalidomide
200 mg orally on days 1-28 of 28 day cycle

Drug: zoledronic acid
4 mg^2 by IV on day 1 every 84 days for 1 year and once per year thereafter

Experimental: Arm II: ZLD
Zoledronic acid (ZLD)
Drug: zoledronic acid
4 mg^2 by IV on day 1 every 84 days for 1 year and once per year thereafter

Primary Outcome Measures :
  1. Time to Disease Progression (TTP) [ Time Frame: randomization to progression (up to 5 years) ]
    Time to disease progression (TTP) was defined as the time from randomization to the earliest documentation of disease progression. Participants were followed for a maximum of 5 years from registration. The median OS with 95% CI was estimated using the Kaplan Meier method, a two-sided (stratified) log-rank test was calculated.

Secondary Outcome Measures :
  1. 12-month Progression-free Survival (PFS) [ Time Frame: 12 months ]
    PFS at 12 months is a dichotomized outcome indicating whether or not a participant was progression free (and alive) at 12 months from the date of randomization.

  2. Number of Participants With a Confirmed Response (Complete Response [CR], Very Good Partial Response [VGPR] or Partial Response [PR]) on Two Consecutive Evaluations at Least 2 Weeks Apart in the First 12 Months of Treatment [ Time Frame: 12 months ]

    Response is defined as follows:

    • CR: Complete disappearance of M-protein from serum & urine on immunofixation, <5% plasma cells in bone marrow (BM)
    • VGPR: >=90% reduction in serum M-component; Urine M-Component <100 mg per 24 hours; <=5% plasma cells in BM
    • PR: >= 50% reduction in serum M-Component and/or Urine M-Component >= 90% reduction or <200 mg per 24 hours; or >= 50% decrease in difference between involved and uninvolved FLC levels

  3. Duration of Response (Complete Response, Partial Response, and Very Good Partial Response) [ Time Frame: time from start of response to progression (up to 5 years) ]
    Duration of response (DOR) is defined as the time from first documentation of response (CR, VGPR or PR) to disease progression. The median DOR with 95% CI was estimated using the Kaplan Meier method

  4. Time to Subsequent Treatment [ Time Frame: time from end of treatment to subsequent treatment (up to 5 years) ]
    Time to subsequent treatment (TTS) was defined as time from end of active (protocol) treatment to the start of subsequent treatment for participants with progressive disease. The median TTS with 95% CI was estimated using the Kaplan Meier method

  5. Time to Treatment Failure [ Time Frame: time from randomization to treatment failure (up to 5 years) ]
    Time to treatment failure (TTF) was defined as the time from randomization to the date at which the patient was removed from (protocol) treatment due to disease progression, unacceptable toxicity, participant refusal or death. The median TTF with 95% CI was estimated using the Kaplan Meier method

  6. Number of Participants With Severe (Grade 3, 4 or 5) Adverse Events [ Time Frame: During treatment (up to 5 years) ]

    Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 2.

    Description of Grades:

    Grade 1: Mild Grade 2: Moderate Grade 3: Severe Grade 4: Life-threatening Grade 5: Death

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of multiple myeloma (MM)

    • Previously untreated asymptomatic disease
    • No requirement for immediate chemotherapy for active MM, such as hypercalcemia from myeloma or painful bone lesions
  • No solitary plasmacytoma
  • Measurable or evaluable disease as defined by one of the following:

    • Serum monoclonal protein ≥ 1.0 g by protein electrophoresis
    • More than 200 mg of monoclonal protein in the urine by 24-hour electrophoresis
    • Measurable soft tissue plasmacytoma by physical exam with ruler or by MRI or positron emission tomography/CT scan

      • If the only measurable lesion is the plasmacytoma, it must be ≥ 1.5 cm in 1 dimension
  • Must have ≥ 10% plasma cells as measured on the bone marrow aspirate, bone marrow biopsy, or labeling index
  • No amyloidosis


  • Performance status 0-2
  • Absolute neutrophil count ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Hemoglobin ≥ 8.0 g/dL
  • Creatinine ≤ 2.0 mg/dL (elevation above normal range should not be felt to be related to myeloma)
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use 2 methods of effective contraception 4 weeks before, during, and for 4 weeks after completion of study treatment
  • No uncontrolled infection
  • No other active malignancy
  • No New York Heart Association class III or IV heart disease
  • No pre-existing neuropathy ≥ grade 2
  • No concurrent major dental work


  • See Disease Characteristics
  • Prior corticosteroids (for nonmalignant disorders) allowed
  • Prior therapy with experimental agents not shown to have significant activity in MM, such as clarithromycin, dehydroepiandrosterone, and anakinra allowed
  • No prior thalidomide or corticosteroids for MM
  • No more than 3 doses of IV zoledronate or pamidronate within the past 12 months
  • At least 3 months since prior radiotherapy, including radiotherapy for solitary plasmacytoma
  • No concurrent oral bisphosphonate therapy for osteoporosis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00432458

Layout table for location information
United States, Arizona
Mayo Clinic Scottsdale
Scottsdale, Arizona, United States, 85259-5499
United States, Florida
Mayo Clinic - Jacksonville
Jacksonville, Florida, United States, 32224
United States, Minnesota
Mayo Clinic Cancer Center
Rochester, Minnesota, United States, 55905
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Mayo Clinic
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Thomas E. Witzig, MD Mayo Clinic
Principal Investigator: Craig Reeder, M.D. Mayo Clinic
Principal Investigator: Vivek Roy, M.D. Mayo Clinic

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Mayo Clinic Identifier: NCT00432458     History of Changes
Other Study ID Numbers: CDR0000530050
P30CA015083 ( U.S. NIH Grant/Contract )
MC0289 ( Other Identifier: Mayo Clinic Cancer Center )
421-03 ( Other Identifier: Mayo Clinic IRB )
First Posted: February 7, 2007    Key Record Dates
Results First Posted: July 4, 2012
Last Update Posted: July 4, 2012
Last Verified: June 2012
Keywords provided by Mayo Clinic:
stage I multiple myeloma
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Zoledronic Acid
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents
Bone Density Conservation Agents